ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And DoneTM ...

We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and ...

Target Audience The intended audience for the activity is US-based ophthalmologists, retina specialists, and optometrists involved in the management of retinal diseases.

ANI Pharmaceuticals' Q2 2025 earnings report highlights record revenues, strong Cortrophin Gel demand, and raised guidance.